Skip to main content

Bulletin from the Annual General Meeting in Enzymatica AB (publ)

Press Release   •   May 19, 2014 14:00 GMT

Enzymatica held its Annual General Meeting today May 19, 2014, in Lund. The meeting resolved upon the following:

Appropriation of profit/loss

The AGM voted in favour of adopting the income statements and the balance sheets of the group and parent company and resolved to carry forward the funds available at the AGM and, consequently, resolved not to distribute any dividend for the financial year 2013.

Discharge from liability for the members of the Board of Directors and the CEO

The AGM discharged the Board of Directors and the CEO from liability.

Board of Directors and remuneration

The AGM resolved to re-elect Christian Westin Jansson, Fredrik Lindberg, Jörgen Rexö and Anders Jungbeck and to elect Marianne Dicander Alexandersson as new member of the Board of Directors. Christian Westin Jansson was also re-elected Chairman of the Board.

The AGM resolved that the total fees to the Board of Directors will amount to SEK 540,000, excluding remuneration for committee work, of which SEK 180,000 will be paid to the Chairman and
SEK 120,000 to each of the other members elected at the AGM and not employed by the company. SEK 50,000 will be paid for work performed by the Chairman of the Audit Committee and no remuneration will be paid to the other members. No remuneration will be paid to the members of the Remuneration Committee.


The AGM also resolved in accordance with the Board of Directors’ proposal on guidelines for remuneration of executive management and adopted principles for the Nomination Committee.

This is a translation of the Swedish announcement. When in doubt, the Swedish wording prevails.

For more information, please contact:

Michael Edelborg Christensen, CEO Enzymatica AB (publ)
Phone: +46 768 14 41 66. Mail:


This information was released for public disclosure on May 19, 2014 at 3.00 p.m. CET.

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »

Attached Files

PDF document

Comments (0)

Add comment